


SARS-CoV-2 Mpro-IN-9

Cat. No.:	HY-155527
CAS No.:	2754370-99-3
Molecular Formula:	C ₂₀ H ₁₄ N ₂ O ₄
Molecular Weight:	346.34
Target:	SARS-CoV
Pathway:	Anti-infection
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	SARS-CoV-2 Mpro-IN-9 (compound c7) is a nonpeptidic, noncovalent SARS-CoV-2 M ^{PRO} inhibitor (IC ₅₀ =0.085 μM), with improved physicochemical and drug metabolism and pharmacokinetics (DMPK) properties. SARS-CoV-2 Mpro-IN-9 inhibits viral replication (EC ₅₀ =1.10 μM) in SARS-CoV-2-infected Vero E6 cells, while exhibits low cytotoxic effects (CC ₅₀ >50 μM) ^[1] .
IC₅₀ & Target	IC ₅₀ : 0.085 μM (SARS-CoV-2), EC ₅₀ : 1.10 μM (viral replication) ^[1]

REFERENCES

[1]. Zhang K, et al. Discovery of quinazolin-4-one-based non-covalent inhibitors targeting the severe acute respiratory syndrome coronavirus 2 main protease (SARS-CoV-2 Mpro). *Eur J Med Chem.* 2023 Sep 5;257:115487.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA